BlackRock Fund Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

BlackRock Fund Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$61K	Buy	58,345 +12,960	+29%	+$14.8K	﹤0.01%	3714
2016 Q3	$49K	Buy	45,385 +33,201	+272%	+$29.9K	﹤0.01%	3786
2016 Q2	$9K	Sell	12,184 -1,952,716	-99%	-$1.57M	﹤0.01%	4007
2016 Q1	$2.3M	Sell	1,964,900 -77,601	-4%	-$120K	﹤0.01%	3041
2015 Q4	$5M	Buy	2,042,501 +84,216	+4%	+$241K	﹤0.01%	2833
2015 Q3	$5.88M	Sell	1,958,285 -18,707	-0.9%	-$80.7K	﹤0.01%	2707
2015 Q2	$8.16M	Buy	1,976,992 +1,792,219	+970%	+$7.14M	﹤0.01%	2625
2015 Q1	$800K	Sell	184,773 -3,685	-2%	-$13.3K	﹤0.01%	3226
2014 Q4	$560K	Buy	188,458 +12,798	+7%	+$35.1K	﹤0.01%	3257
2014 Q3	$583K	Buy	175,660 +16,804	+11%	+$43.9K	﹤0.01%	3212
2014 Q2	$402K	Buy	+158,856	New	+$339K	﹤0.01%	3250

Other funds holding CPRX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

TCM

Tanaka Capital Management New York $59.9M AUM

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock Fund Advisors's CPRX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 29% in Q4 2016, buying an estimated $14.8K and bringing the position to 58,345 shares worth $61K. The position accounts for ﹤0.01% of the portfolio, ranked #3714.

BlackRock Fund Advisors first reported a position in CPRX in Q2 2014 and has held it in 11 quarters since. The position peaked at $8.16M in Q2 2015. 54 funds tracked by Wall St. Rank hold CPRX as of Q4 2016.

BlackRock Fund Advisors held 58,345 shares of Catalyst Pharmaceutical worth $61K as of Q4 2016.
BlackRock Fund Advisors bought 12,960 Catalyst Pharmaceutical shares in Q4 2016, an estimated $14.8K.
Catalyst Pharmaceutical made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3714 holding.
BlackRock Fund Advisors first reported a position in Catalyst Pharmaceutical in Q2 2014 and has held it in 11 quarters since.
BlackRock Fund Advisors's Catalyst Pharmaceutical position peaked at $8.16M in Q2 2015.
54 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.